ArticleHead and neck pathology2025
Sinonasal Tract Osteochondromyxoma: Future Directions Beyond Morphologic Description.
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent delineation of sinonasal tract osteochondromyxoma (STOX) as a distinct entity, characterized by PRKAR1A inactivation and association with Carney complex, represents a significant step forward in head and neck pathology (Bishop in Head Neck Pathol 19(1):117, 2025). CRITICAL ANALYSIS: While the diagnostic criteria proposed by Bishop et al. are valuable, several substantive limitations necessitate scrutiny. The morphologic overlap with nasal chondromesenchymal hamartoma (NCMH) remains a formidable diagnostic challenge in small biopsies, and the reliance on PRKAR1A immunohistochemistry requires rigorous validation regarding its sensitivity and specificity, particularly in decalcified specimens. The study's characterization of the tumor's "locally aggressive" behavior lacks granularity, leaving critical management questions-such as optimal surgical margins and the potential for molecularly targeted therapies-unanswered. Furthermore, the vital link to Carney complex is not translated into a structured framework for interdisciplinary patient management and genetic counseling. FUTURE DIRECTIONS: To transition from pathologic description to clinical impact, future efforts must focus on validating diagnostic criteria in large, multi-institutional cohorts, integrating comprehensive molecular profiling to uncover therapeutic vulnerabilities, and establishing evidence-based management protocols. The pathologic recognition of STOX must be seamlessly connected to systematic genetic evaluation and long-term monitoring, fulfilling the translational imperative of this diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.